Investigative Safety Scientist/Toxicologist
Incyte
Summary
A global biopharmaceutical company on a mission to Solve On, Incyte follows science to find solutions for patients with unmet medical needs. Through the discovery, development, and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Hematology, Oncology and Inflammation and Autoimmunity.
Job description
Overview
A global biopharmaceutical company on a mission to Solve On, Incyte follows science to find solutions for patients with unmet medical needs. Through the discovery, development, and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Hematology, Oncology and Inflammation and Autoimmunity.
Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe, and Asia.
Role
The Investigative Safety Scientist will conduct safety assessments to support the discovery and development of proprietary therapeutics. They will work across hematology, oncology, and inflammation portfolios to ensure the safety profile of new medicines.
Requirements
- Expertise in toxicology and safety science within a biopharmaceutical context
- Strong background in drug development processes
- Strong background in scientific research methodologies
- 5-10 years of relevant experience
Company overview
Incyte Corporation is a leading biopharmaceutical company specializing in the discovery, development, and commercialization of proprietary therapeutics. Founded as a genomics information company, Incyte has evolved into a prominent player in the pharmaceutical industry with a strong focus on oncology and inflammatory diseases. The company's flagship product, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor approved for treating polycythemia vera, myelofibrosis, and steroid-refractory acute graft-versus-host disease. With research facilities in Palo Alto, California, Newark, Delaware, and San Diego, California, Incyte leverages its expertise in medicinal chemistry, molecular biology, and genomic technologies to develop novel small molecule and protein therapeutics. The company maintains a significant intellectual property portfolio covering human genes and proteins, which it licenses to leading pharmaceutical and biotechnology companies worldwide. Incyte's strategic approach combines innovative drug discovery with robust clinical development programs, positioning it as a key contributor to advancing treatments for cancer, inflammatory conditions, and other serious medical disorders.